Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6

Journal of Hepatology

Volumn 68, Issue 4, 2018, Pages 814-826

  Asselah, Tarik ^a   Hassanein, Tarek ^b   Waked, Imam ^c   Mansouri, Abdellah ^a   Dusheiko, Geoffrey ^d   Gane, Edward ^e  

^a BEAUJON HOSPITAL   (France)

^b Southern California Liver Centers and Southern California Research Center   (United States)

^c National Liver Institute   (Egypt)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Chronic hepatitis C; Direct acting antivirals; Epidemiology; HCV elimination; Screening

Indexed keywords

ANTIVIRUS AGENT; ELBASVIR PLUS GRAZOPREVIR; GLECAPREVIR PLUS PIBRENTASVIR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RAVIDASVIR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR;

DISEASE ELIMINATION; DRUG EFFICACY; EC50; EPIDEMIOLOGICAL DATA; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; IN VITRO STUDY; LOW INCOME COUNTRY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; REVIEW; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; CHRONIC HEPATITIS C; CLASSIFICATION; COMBINATION DRUG THERAPY; DEVELOPING COUNTRY; GENETICS; GENOTYPE; HEPACIVIRUS;

ANTIVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 85041135983     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.11.037     Document Type: Review

References (91)

1. WHO global hepatitis report 2017 (available: www.who.int/hepatitis/publications/global-hepatitis-report2017).
2. Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
3. Abdel-Razek, W., Waked, I., Optimal therapy in genotype 4 chronic hepatitis C: finally cured?. Liver Int 35 (2015), 27–34.
4. Frank, C., Mohamed, M.K., Strickland, G.T., Lavanchy, D., Arthur, R.R., Magder, L.S., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 (2000), 887–891.
5. Asselah, T., Perumalswami, P.V., Dieterich, D., Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity. Liver Int 34 (2014), 1447–1451.
6. Smuts, H.E., Kannemeyer, J., Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 33 (1995), 1679–1681.
7. Prabdial-Sing, N., Chirwa, T., Thaver, J., Smuts, H., Vermeulen, M., Suchard, M., et al. Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008–2012. J Viral Hepat 23 (2016), 881–888.
8. van Doorn, L.J., Kleter, G.E., Stuyver, L., Maertens, G., Brouwer, J.T., Schalm, S.W., et al. Sequence analysis of hepatitis C virus genotypes 1 to 5 reveals multiple novel subtypes in the Benelux countries. J Gen Virol 76 (1995), 1871–1876.
9. Henquell, C., Cartau, C., Abergel, A., Laurichesse, H., Regagnon, C., De Champs, C., et al. High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 42 (2004), 3030–3035.
10. Martinot-Peignoux, M., Roudot-Thoraval, F., Mendel, I., Coste, J., Izopet, J., Duverlie, G., et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 6 (1999), 435–443.
11. Legrand-Abravanel, F., Sandres-Sauné, K., Barange, K., Alric, L., Moreau, J., Desmorat, P., et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 189 (2004), 1397–1400.
12. Abergel, A., Ughetto, S., Dubost, S., Bonny, C., Aublet-Cuvelier, B., Delarocque-Astagneau, E., et al. The epidemiology and virology of hepatitis C virus genotype 5 in central France. Aliment Pharmacol Ther 26 (2007), 1437–1446.
13. Karatapanis, S., Tsoplou, P., Papastergiou, V., Vasiageorgi, A., Stampori, M., Saitis, I., et al. Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island. J Med Virol 84 (2012), 223–228.
14. Antaki, N., Haddad, M., Kebbewar, K., Abdelwahab, J., Hamed, O., Aaraj, R., et al. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect 137 (2009), 79–84.
15. Jover, R., Pérez-Serra, J., de Vera, F., Alamo, J.M., Muñoz, C., Yago, C., et al. Infection by genotype 5a of HCV in a district of southeast Spain. Am J Gastroenterol 96 (2001), 3042–3043.
16. Wantuck, J.M., Ahmed, A., Nguyen, M.H., Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 39 (2014), 137–147.
17. Thong, V.D., Akkarathamrongsin, S., Poovorawan, K., Tangkijvanich, P., Poovorawan, Y., Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol 20 (2014), 2927–2940.
18. Zhou, N., Hernandez, D., Ueland, J., Yang, X.Y., Yu, F., Sims, K., et al. NS5A Sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. J Infect Dis 213 (2016), 206–215.
19. Asselah, T., Bourliere, M., Hepatitis C virus current and evolving treatments for genotype 4. Gastroenterol Clin North Am 44 (2015), 859–870.
20. Smith, D.B., Bukh, J., Kuiken, C., Muerhoff, A.S., Rice, C.M., Stapleton, J.T., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 (2014), 318–327.
21. Estrabaud, E., Vidaud, M., Marcellin, P., Asselah, T., Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 57 (2012), 1110–1125.
22. Asselah, T., De Muynck, S., Broët, P., Masliah-Planchon, J., Blanluet, M., Bièche, I., et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 56 (2012), 527–532.
23. Bonny, C., Fontaine, H., Poynard, T., Hézode, C., Larrey, D., Marcellin, P., et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 24 (2006), 593–600.
24. Seto, W.K., Lai, C.L., Fung, J., Hung, I., Yuen, J., Young, J., et al. Natural history of chronic hepatitis C: genotype 1 vs. genotype 6. J Hepatol 53 (2010), 444–448.
25. Marcellin, P., Cheinquer, H., Curescu, M., Dusheiko, G.M., Ferenci, P., Horban, A., et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 56 (2012), 2039–2050.
26. Ferenci, P., Laferl, H., Scherzer, T.M., Gschwantler, M., Maieron, A., Brunner, H., et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135 (2008), 451–458.
27. Asselah, T., Esmat, G., Sanai, F.M., Goulis, I., Messinger, D., Bakalos, G., et al. Simple predictive model for identifying patients with chronic hepatitis C and hepatitis C virus genotype 4 infection with a high probability of sustained virologic response with peginterferon alfa-2a/ribavirin: pooled analysis of data from two large. International Cohort Studies Adv Ther 33 (2016), 1797–1813.
28. Devaki, P., Jencks, D., Yee, B.E., Nguyen, M.H., Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients. Hepatol Int 9 (2015), 431–437.
29. Nguyen, N.H., McCormack, S.A., Yee, B.E., Devaki, P., Jencks, D., Chao, D.T., et al. Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks. Hepatol Int 8 (2014), 540–549.
30. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989), 359–362.
31. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., Replication of sub-genomic hepatitis C virus RNAs in a hepatoma cell line. Science, 285, 1999, 3.
32. Blight, K.J., Kolykhalov, A.A., Rice, C.M., Efficient initiation of HCV RNA replication in cell culture. Science 290 (2000), 1972–1974.
33. Lamarre, D., Anderson, P.C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003), 186–189.
34. Zeuzem, S., Soriano, V., Asselah, T., Bronowicki, J.P., Lohse, A.W., Müllhaupt, B., et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 369 (2013), 630–639.
35. Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465 (2010), 96–100.
36. Schinazi, R., Halfon, P., Marcellin, P., Asselah, T., HCV direct-acting antiviral agents: The best interferon-free combinations. Liver Int 34 (2014), 69–78.
37. Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87 (1996), 343–355.
38. Yao, N., Hesson, T., Cable, M., Hong, Z., Kwong, A.D., Le, H.V., et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 4 (1997), 463–467.
39. Halfon, P., Locarnini, S., Hepatitis C virus resistance to protease inhibitors. J Hepatol 55 (2011), 192–206.
40. Koch, U., Narjes, F., Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 7 (2007), 1302–1329.
41. Gish, R.G., Meanwell, N.A., The NS5A replication complex inhibitors: Difference makers?. Clin Liver Dis 15 (2011), 627–639.
42. Hézode, C., Hirschfield, G.M., Ghesquiere, W., Sievert, W., Rodriguez-Torres, M., Shafran, S., et al. Randomized study of daclatasvir plus peginterferon alfa-2a and ribavirin for previously untreated chronic hepatitis C. Gut 64 (2015), 948–956.
43. Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
44. Asselah, T., Moreno, C., Sarrazin, C., Gschwantler, M., Foster, G.R., Craxí, A., et al. Efficacy of a 12-week simeprevir plus peginterferon/ribavirin (PR) regimen in treatment-naïve patients with hepatitis C virus (HCV) genotype 4 (GT4) infection and mild-to-moderate fibrosis displaying early on-treatment virologic response. PLoS One, 12, 2017, e0168713.
45. Ruane, P.J., Ain, D., Stryker, R., Meshrekey, R., Soliman, M., Wolfe, P.R., et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 62 (2015), 1040–1046.
46. Doss, W., Shiha, G., Hassany, M., Soliman, R., Fouad, R., Khairy, M., et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63 (2015), 581–585.
47. Elsharkawy, A., Fouad, R., Elakel, W., El-Raziky, M., Hassany, M., Shiha, G., et al. Sofosbuvir based treatment regimens: Real life results of 14,409 chronic HCV genotype 4 patients. Aliment Pharmacol Ther 45 (2017), 681–687.
48. Buti, M., Calleja, J.L., Lens, S., Diago, M., Ortega, E., Crespo, J., et al. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther 45 (2017), 468–475.
49. El Raziky, M., Gamil, M., Ashour, M.K., Abdel Sameea, E., Doss, W., Hamada, Y., et al. Simeprevir plus sofosbuvir for 8 or 12 weeks in treatment-naïve and -experienced hepatitis C virus genotype 4 patients with or without cirrhosis. J Viral Hepat 24 (2017), 102–110.
50. Eletreby, R., Elakel, W., Said, M., El Kassas, M., Seif, S., Elbaz, T., et al. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int 37 (2017), 534–541.
51. Poordad, F., Schiff, E.R., Vierling, J.M., Landis, C., Fontana, R.J., Yang, R., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
52. Luetkemeyer, A.F., McDonald, C., Ramgopal, M., Noviello, S., Bhore, R., Ackerman, P., 12 Weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 Study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis 62 (2016), 1489–1496.
53. Welzel, T.M., Petersen, J., Herzer, K., Ferenci, P., Gschwantler, M., Wedemeyer, H., et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 65 (2016), 1861–1870.
54. Omar H, El Akel W, Elbaz T, El Kassas M, El Saeed K, El Shazly H, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18,378 patients in Egypt. Submitted.
55. Abergel, A., Metivier, S., Samuel, D., Jiang, D., Kersey, K., Pang, P.S., et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 64 (2016), 1049–1056.
56. Camus, G., Han, B., Asselah, T., Hsieh, D., Dvory-Sobol, H., Lu, J., et al. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. J Viral Hepat, 2018 in press.
57. Kohli, A., Kapoor, R., Sims, Z., Nelson, A., Sidharthan, S., Lam, B., et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 15 (2015), 1049–1054.
58. Shiha, G., Waked, I., Soliman, R.E., Abdelrazek, W., Hassany, M., Fouad, R., et al. Ledipasvir/sofosbuvir in egyptian patients with chronic genotype 4 HCV infection. Hepatology 64 (2016), 436A–437A [AASLD 2016, Abstract # 879].
59. Feld, J.J., Jacobson, I.M., Hezode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
60. Asselah, T., Bourgeois, S., Pianko, S., Zeuzem, S., Sulkowski, M., Foster, G.R., et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1–6 and compensated cirrhosis or advanced fibrosis. Liver Int, 2018 in press.
61. Jacobson, I.M., Lawitz, E., Gane, E.J., Willems, B.E., Ruane, P.J., Nahass, R.G., et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomised trials. Gastroenterology 153 (2017), 113–122.
62. Hezode, C., Asselah, T., Reddy, K.R., Hassanein, T., Berenguer, M., Fleischer-Stepniewska, K., et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385 (2015), 2502–2509.
63. Asselah, T., Hézode, C., Qaqish, R.B., ElKhashab, M., Hassanein, T., Papatheodoridis, G., et al. Co-formulated ombitasvir and paritaprevir/ritonavir with ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a randomised, open-label trial. Lancet Gastroenterol Hepatol 1 (2016), 25–35.
64. Waked, I., Shiha, S., Qaqish, R.B., Esmat, G., Yosry, A., Hassany, M., et al. Co-formulated ombitasvir and paritaprevir/ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a randomised, open-label trial. Lancet Gastroenterol Hepatol 1 (2016), 36–45.
65. Ng, T., Krishnan, P., Pilot-Matias, T., Kati, W., Schnell, G., Beyer, J., et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother, 61, 2017.
66. Asselah, T., Kowdley, K.V., Zadeikis, N., Wang, S., Hassanein, T., Horsmans, Y., et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol, 2018 in press.
67. Asante-Appiah, E., Curry, S., McMonagle, P., Ingravallo, P., Chase, R., Nickle, D., Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons. Antimicrob Agents Chemother, 61, 2017 [pii: e00363-17].
68. Asselah, T., Reesink, H., Gerstoft, J., de Ledinghen, V., Pockros, P., Robertson, M., et al. High efficacy of elbasvir and grazoprevir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: a pooled analysis. Hepatology, 2015 [AASLD; abstract 251].
69. Roth, D., Nelson, D.R., Bruchfeld, A., Liapakis, A., Silva, M., Monsour, H. Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386 (2015), 1537–1545.
70. Kramer JR, Puenpatom A, Erickson K, Cao Y, Smith DL, El-Serag HB, et al. Effectiveness of elbasvir/grazoprevir in patients with chronic hepatitis C and chronic kidney disease: results from the veterans affairs system. In: 68th annual meeting of the American association for the study of liver diseases, October 20–24. Washington DC, USA; 2017 [abstract 1113].
71. Esmat, G., Elbaz, T., El Raziky, M., Gomaa, A., Abouelkhair, M., El Deen, H.G., et al. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis c genotype-4. J Hepatol S0168–8278 (2017), 32286–32289.
72. Abergel, A., Asselah, T., Metivier, S., Kersey, K., Jiang, D., Mo, H., et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 16 (2016), 459–464.
73. Gane, E.J., Hyland, R.H., An, D., Svarovskaia, E., Pang, P.S., Brainard, D., et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149 (2015), 1454–1461.
74. Nguyen M, et al. LC2017-RS-1361.
75. Hassanein T, Wyles D, Wang S, Kwo PY, Shiffman ML, Younes Z, et al. SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration. AASLD 2016, Boston. #LB-15.
76. Martinot-Peignoux, M., Stern, C., Maylin, S., Ripault, M.P., Boyer, N., Leclere, L., et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51 (2010), 1122–1126.
77. Maylin, S., Martinot-Peignoux, M., Moucari, R., Boyer, N., Ripault, M.P., Cazals-Hatem, D., et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 135 (2008), 821–829.
78. Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
79. Afdhal, N., Everson, G.T., Calleja, J.L., McCaughan, G.W., Bosch, J., Brainard, D.M., et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat 24 (2017), 823–831.
80. Kim RW, Mannalithara A, Lee H, Osinusi A, Schall REA, Brainard DM. Survival benefit of direct acting antiviral therapy in patients with decompensated cirrhosis. Hepatology 2017;66:LB27.
81. Younossi, Z.M., Stepanova, M., Asselah, T., et al. Hepatitis C in patients with minimal or no hepatic fibrosis: the impact of treatment and sustained virologic response on patient-reported outcomes. Clin Infect Dis, 2018 in press.
82. Appourchaux, K., Dokmak, S., Resche-Rigon, M., Treton, X., Lapalus, M., Gattolliat, C.H., et al. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep, 12, 2016, 34935.
83. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 66 (2017), 153–194.
84. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org.
85. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 165 (2016), 625–634.
86. Lalezari, J., Sullivan, J.G., Varunok, P., Galen, E., Kowdley, K.V., Rustgi, V., et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 63 (2015), 364–369.
87. Moser, S., Schütz, A., Marchart, K., Kalchbrenner, D., Rechberger, G., Luhn, J., et al. Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy. J Hepatol, 66, 2017, S740.
88. Grebely, J., Dalgard, O., Conway, B., Cunningham, E., Bruggmann, P., Hajarizadeh, B., et al. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study. J Hepatol, 66, 2017, S513.
89. Dore, G., Grebely, J., Altice, F., et al. Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-STAR part B [AASLD Liver Meeting abstract 195]. Hepatology, 66, 2017.
90. Bourlière, M., Gordon, S.C., Flamm, S.L., Cooper, C.L., Ramji, A., Tong, M., et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376 (2017), 2134–2146.
91. Poordad, F., Felizarta, F., Asatryan, A., Sulkowski, M.S., Reindollar, R.W., Landis, C.S., et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66 (2017), 389–397.